DuPont Pharmaceuticals Highlights Growth Strategy at Socma Meeting.

Chemical Market Reporter, March, 2000 by MIRASOL, FELIZA

AMID THE ROAR of giant' drug companies dominating the pharmaceutical landscape, DuPont Pharmaceuticals Company, the wholly owned subsidiary of E. I. du Pont de Nemours & Co., is moving toward joining the top-ranking pharmaceutical firms by maintaining smaller-scale manufacturing flexibility and expanding in research and development as well as sales and marketing.

"We believe we have an excellent R&D organization with a strong pipeline that bodes well for our future. We also believe we are a very good sales and marketing company, as demonstrated in the joint venture we had with Merck. We were about $500 million in revenue. Today, we are at $2 billion and climbing," Mr. Heiser says.

As a roughly $2 billion company, DuPont Pharmaceuticals ranks...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here